Published in Br J Clin Pharmacol on October 24, 2007
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab (2008) 1.45
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf (2010) 1.10
Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc Health Risk Manag (2008) 0.93
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol (2012) 0.87
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. J Korean Med Sci (2013) 0.83
Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther (2013) 0.79
Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. Int J Med Sci (2013) 0.78
Pharmacokinetic(s) matters: stroke treatment et cetera. Br J Clin Pharmacol (2008) 0.75
Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin. Br J Clin Pharmacol (2016) 0.75
Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells. Sci Rep (2016) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet (2002) 4.29
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 3.63
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem (1993) 2.93
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther (2005) 2.85
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab (2004) 2.21
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem (2003) 1.84
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab (2005) 1.76
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care (2004) 1.75
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab (1993) 1.61
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol (1999) 1.60
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res (2005) 1.45
Age-dependent changes of the kidneys: pharmacological implications. Gerontology (1999) 1.41
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab (2005) 1.39
Pharmacokinetics in older persons. Am J Geriatr Pharmacother (2004) 1.35
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res (2006) 1.30
Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev (2002) 1.29
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol (2007) 1.10
Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care (1998) 0.98
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res (2005) 0.86
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 3.88
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol (2005) 3.14
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21
c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ Res (2002) 2.11
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab (2007) 2.02
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem (2003) 1.95
Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A (2005) 1.84
Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest (2009) 1.83
Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res (2003) 1.81
Myocardin induces cardiomyocyte hypertrophy. Circ Res (2006) 1.74
Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. J Mol Cell Cardiol (2009) 1.72
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab (2007) 1.70
Divergent mitochondrial biogenesis responses in human cardiomyopathy. Circulation (2013) 1.69
Junctophilin type 2 is associated with caveolin-3 and is down-regulated in the hypertrophic and dilated cardiomyopathies. Biochem Biophys Res Commun (2004) 1.69
Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol (2010) 1.65
The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest (2003) 1.61
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet (2007) 1.57
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol (2006) 1.56
Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res (2009) 1.52
Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am J Physiol Heart Circ Physiol (2004) 1.51
Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther (2004) 1.49
A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development. Genes Dev (2007) 1.49
p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res (2007) 1.48
Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res (2005) 1.48
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation (2008) 1.45
Atrial chamber-specific expression of sarcolipin is regulated during development and hypertrophic remodeling. J Biol Chem (2003) 1.44
Hybrid mouse diversity panel: a panel of inbred mouse strains suitable for analysis of complex genetic traits. Mamm Genome (2012) 1.43
Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol (2005) 1.42
Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. Mol Cell Proteomics (2010) 1.41
Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res (2011) 1.41
Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells. J Clin Invest (2009) 1.36
Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ Res (2010) 1.34
p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res (2002) 1.34
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol (2004) 1.33
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab (2013) 1.30
TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J Biol Chem (2005) 1.28
Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J Clin Invest (2010) 1.28
An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet (2010) 1.26
p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation (2005) 1.26
Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J Clin Invest (2011) 1.26
Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. J Mol Cell Cardiol (2008) 1.25
Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation (2005) 1.24
Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med (2004) 1.23
The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol (2010) 1.22
Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development (2012) 1.21
Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? Cardiovasc Res (2011) 1.18
Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor. J Clin Invest (2007) 1.17
Human immunodeficiency virus type 1 hnRNP A/B-dependent exonic splicing silencer ESSV antagonizes binding of U2AF65 to viral polypyrimidine tracts. Mol Cell Biol (2003) 1.14
Klf15 orchestrates circadian nitrogen homeostasis. Cell Metab (2012) 1.14
Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol (2004) 1.14
Modulation of in vivo cardiac function by myocyte-specific nitric oxide synthase-3. Circ Res (2004) 1.13
"Good enough solutions" and the genetics of complex diseases. Circ Res (2012) 1.13
MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res (2010) 1.12
A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One (2007) 1.12
Overexpression of bone morphogenetic protein 10 in myocardium disrupts cardiac postnatal hypertrophic growth. J Biol Chem (2006) 1.12
Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol (2003) 1.11
Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol (2005) 1.10
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol (2007) 1.10
Functional diversity of mammalian type 2C protein phosphatase isoforms: new tales from an old family. Clin Exp Pharmacol Physiol (2008) 1.09
Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum Mol Genet (2010) 1.09
Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology. Circulation (2003) 1.08
Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte. Circ Res (2010) 1.08
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet (2007) 1.07
Targeted activation of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects. J Biol Chem (2004) 1.07
Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J (2003) 1.06
Systems-based approaches to cardiovascular disease. Nat Rev Cardiol (2012) 1.04
Quantitative analysis of the chromatin proteome in disease reveals remodeling principles and identifies high mobility group protein B2 as a regulator of hypertrophic growth. Mol Cell Proteomics (2012) 1.03
Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet (2008) 1.02
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol (2005) 1.02
Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol (2007) 1.02
Induction of apoptosis in vascular smooth muscle cells by mechanical stretch. Am J Physiol Heart Circ Physiol (2002) 1.02
Protective role of transient pore openings in calcium handling by cardiac mitochondria. J Biol Chem (2011) 1.01
Gi-biased β2AR signaling links GRK2 upregulation to heart failure. Circ Res (2011) 1.01
Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc Med (2006) 1.00
Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. J Mol Cell Cardiol (2010) 0.99
Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos (2007) 0.99
Protein kinetic signatures of the remodeling heart following isoproterenol stimulation. J Clin Invest (2014) 0.99
Accurate homologous recombination is a prominent double-strand break repair pathway in mammalian chromosomes and is modulated by mismatch repair protein Msh2. Mol Cell Biol (2007) 0.98
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol (2008) 0.98
A maize QTL for silk maysin levels contains duplicated Myb-homologous genes which jointly regulate flavone biosynthesis. Plant Mol Biol (2003) 0.98
Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation. Physiol Genomics (2005) 0.97
JNK activation decreases PP2A regulatory subunit B56alpha expression and mRNA stability and increases AUF1 expression in cardiomyocytes. Am J Physiol Heart Circ Physiol (2006) 0.96
Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos (2007) 0.95
The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Eur J Clin Pharmacol (2008) 0.95
Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. Circulation (2007) 0.93